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Rising Infection Rate in Cardiac Electronic Device 
Implantation; the Role of the AIGISRx® Antibacterial 
Envelope in Prophylaxis
Christopher R. Ellis · Matthew J. Kolek
ABSTRACT 
The implantation of cardiac implantable 
electronic devices (CIED) to prevent sudden 
cardiac death, ameliorate chronic congestive 
heart failure, and correct bradycardia has grown 
rapidly in the past decade. Bacterial infection of 
the device hardware (pacemaker or implantable 
cardioverter defibrillator [ICD] pulse generator, 
and intravascular wires or leads), including the 
tissue pocket, is rising at an even faster rate. The 
source infection inoculation typically occurs at 
the time the device is implanted, revised, or when 
a device generator replacement occurs. This risk 
is clearly related to patient and procedure-specific 
factors, and is reviewed in the present paper. 
Prophylactic preoperative antibiotics, strict 
sterile technique, and limiting procedure times 
may reduce infection risk. A novel Antibacterial 
Envelope (AIGISRx®, TYRX Inc., Monmouth 
Junction, NJ, USA) that is directly implanted 
with the device generator to provide site-specific 
therapy could significantly lower infection risk 
in certain high-risk cases. This may potentially 
reduce inpatient mortality related to endocarditis 
and sepsis, and lower healthcare costs related to 
CIED extraction and re-implantation, which can 
exceed $1 million per case. 
Keywords: antibacterial envelope; device pocket 
infection; endocarditis; implantable cardioverter 
defibrillator; infection prophylaxis pacemaker 
INTRODUCTION
The implantation of permanent cardiac 
implantable electronic devices (CIED) experienced 
an initial phase of rapid growth beginning 
in 1989 following the development of trans-
venous implantable cardioverter defibrillator 
(ICD) leads, allowing pectoral implants. Results 
of clinical trials and incorporation into heart 
care society guidelines for primary prevention 
of sudden death and cardiac resynchronization 
therapy (CRT) for heart failure, have resulted in 
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>600,000 annual worldwide implants in 2010.1,2
A corresponding rise in CIED-related device 
infection has been noted, with a rate exceeding 
that of the increase in device use. The aggressive 
application of expanding indications for CIEDs 
has led to greater numbers of procedures in 
patients with significant comorbid conditions. 
Between 1993-2008 the annual rate of infection in 
a large inpatient registry was 1.6%, with a notable 
rise after 2004, parallel with the expansion of 
CRT pacing, and increases in the percentage 
of patients with diabetes and renal failure.2,3
Device generator replacements, CRT upgrades, 
abandoned hardware, chronic venous occlusion, 
and laser lead extraction for failed hardware have 
increased the complexity of implanted cardiac 
device cases, and potentially leads to longer case 
times, increasing infection risks.2,4 The rising 
trend of CIED-related infection will result in 
increases in morbidity, inpatient mortality risk, 
and the financial burden on the United States 
(US) healthcare system, to an estimated annual 
cost of >$250 million, and this is reviewed in the 
following paper.
Data published in 2006 demonstrated device 
infection rates were rising. A review of device 
implantation data from 1996-2003 showed a 49% 
rise in the number of new CIED implantations in 
the US, from 159,585 in 1996 to 237,720 in 2003. 
ICD insertions mainly accounted for the growth 
(rise of 160% for ICDs vs. 31% for pacemakers). 
During the same period, hospitalizations 
with CIED infection increased 3.1-fold 
(2.8-fold for pacemakers and sixfold for ICDs), 
showing numbers of CIED infection-related 
hospitalizations increased out of proportion 
to rates of new device implants. The mortality 
rate for inpatients with CIED-related infection 
was increased compared to pacemaker or ICD 
device implants without a hospital code for CIED 
infection. After correcting for age, gender, race, 
hospital size, presence of diabetes mellitus, or 
renal failure, CIED infection increased the risk 
of in-hospital death more than twofold (odds 
ratio [OR] 2.41, P=0.001). Predictors of death also 
included older age (OR 1.63 per 20-year increase 
in age, P=0.001) and the presence of renal failure 
(OR 1.76, P=0.001).5
The demographics of patients who received 
CRT-defibrillator (CRT-D) devices in 2011, as 
well as primary prevention ICDs, is pushing the 
boundaries of appropriateness, likely accounting 
for part of the rise in infection rates. Retrospective 
analysis of primary prevention patients with 
renal insufficiency or chronic kidney disease 
suggests an ICD confers no benefit to reducing 
mortality. Patients in whom baseline serum 
creatinine concentration was >2 mg/dL had a 
62% 1 year survival despite an ICD in situ, yet the 
percentage of patients in ICD registries with renal 
insufficiency has risen dramatically since 2004.6,7
Cases requiring lead extraction in the setting of 
infection are associated with a high inpatient 
mortality rate, particularly in patients with 
end-stage renal disease.8 Given the necessity to 
completely remove or extract infected hardware, 
these cases comprise a heavy financial burden to 
the healthcare system. 
An analysis of a retrospective cohort of 
200,219 patients, including 5817 Medicare 
patients admitted for CIED infection in 
the setting of generator implantation, 
replacement, or revision from January 1, 
2007 to December 31, 2007,4 demonstrated 
a 4.6%-11.3% in-hospital mortality rate (rate 
ratio of 4.8-7.7-fold increase). This represented 
an absolute in-hospital mortality increase of 
4.3%-10.5% compared with CIED cases without 
infection. The inpatient length of stay (LOS) was 
longer at 9.6-15 days incremental stay related 
to the presence of device infection (LOS ratio 
2.5-4.0-fold increase), and total cost was $28,676 
to $53,349 per case (ranges represent difference 
between pacemaker, ICD, CRT-pacing [CRT-P] 
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and CRT-D cases). Approximately 40% of the 
incremental cost of care was related to intensive 
care unit admissions, and the most extreme 
cases exceeded a cost of $1 million per case.4 
Using a low estimated implantation volume of 
400,000 annually for pacemaker or ICD systems 
with a 1.6% infection rate, the total estimated 
CIED infections would be 6400. If a case-cost 
to hospitals is $28,676 (pacemaker) to $53,349 
(ICD) per case, and at least two-thirds of these 
400,000 cases are ICD systems, then the annual 
cost of CIED infections in the US would be at a 
minimum $285 million US dollars.
Published randomized clinical trial data 
show infection may be reduced with the routine 
timely use of preoperative antibiotics, and 
choice of chlorhexidine skin prep over iodine-
based solutions.9,10 A novel combined therapy 
device, the AIGISRx® Antibacterial Envelope 
(TYRX Inc., Monmouth Junction, NJ, USA), 
has been approved by the US Food and Drug 
Administration (FDA) for prevention of CRT-
device infection. Retrospective cohort studies 
suggest a significant reduction in infection 
rates, with potential for substantial cost savings, 
particularly if utilized in the highest risk cases.11 
The increased need to reduce device-related 
infection is evident, yet few treatment options 
exist or have been rigorously studied. The present 
study examines the design and mechanism of 
action of the AIGISRx Antibacterial Envelope, 
and reviews available published clinical study 
results, ongoing trials, and practical experience 
of the authors with the use of this product.
RISK FACTORS FOR INFECTION, 
MICROBIOLOGY, AND RATIONALE 
FOR THE AIGISRx ANTIBACTERIAL 
ENVELOPE
Patient-specific and procedure-based factors 
are known to be associated with a higher 
rate of peri-procedural infection including 
pulse generator change-out procedures, 
oral anticoagulant and steroid use, early 
re-intervention, temporary pacing, and systems 
with more than two leads.11 The presence of 
diabetes and chronic renal disease raise the 
expected rate of infection, with end-stage renal 
disease increasing the odds of infection by a 
factor of 4.6-12.12,13 The increasing rate of device 
infection from 2004-2008 may be accounted 
for in part by a rise in the comorbid illnesses of 
diabetes and renal failure as discussed above, and 
illustrated in Figure 1, adapted from Greenspon 
et al.2
The rise in infection rate is also associated 
with a rapid expansion of CRT-P and CRT-D 
systems after results of clinical trials showed 
improved mortality and reduced heart failure 
morbidity with left ventricular or coronary sinus 
pacing in selected patients (chronic systolic 
heart failure [left ventricular ejection fraction 
{LVEF} <35%], QRS duration of >120 ms, and 
left bundle branch block, or ventricular dys-
synchrony).14,15 CRT-P requires attention to 
placement of the left ventricular pacing lead in 
the optimal coronary sinus branch, to optimize 
clinical benefit. This may extend case times by 
~20-90 minutes typically, allowing more time 
for pocket or hardware contamination. 
Outcomes for defibrillator patients within 
90 days of device implant or revision are related 
to the procedural volume of the operating 
physician and procedure volume of the 
hospital. The majority of implanting physicians 
in the lowest volume subgroup have increased 
mechanical complications (OR 1.47, 95% CI 
1.09-1.99) and infection risk (OR 2.47, 95% 
CI 1.18-5.17).16 A study of ICD implantations 
between January 2006 and December 2008 
in the National Cardiovascular Data Registry 
(NCDR) ICD registry shows that the rate of 
any adverse event declined progressively 
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with increasing procedure volume for all ICD 
subtypes (single chamber, dual chamber, 
and biventricular ICDs). Additionally, the 
highest volume, lowest complication quartile 
correspondingly had the highest percentage 
of cardiac electrophysiology board-certified 
implanting physicians.17 Regardless of operator 
volume, skill, or board certification, the rise in 
infection rates affects all implanting physicians 
and hospitals, and steps should be taken to 
reduce these risks.
The most common pathogens responsible 
for CIED infections are Staphylococcus aureus, 
and coagulase-negative staphylococcal species 
(CoNS).12,18 The combination of the antibiotics, 
rifampin and minocycline, are known to have 
in vitro activity against methicillin-resistant 
strains of S. aureus and CoNS. Clinical studies 
incorporating rifampin and minocycline 
into central venous catheters, cerebrospinal 
fluid drains, and hemodialysis catheters have 
demonstrated reduction in device-related 
infections.19-21
AIGISRx DESIGN, ANTIBIOTIC, 
AND ANIMAL STUDY RESULTS
The AIGISRx Antibacterial Envelope is an 
FDA-approved polypropylene mesh envelope 
that releases minocycline and rifampin from 
a bioresorbable polyarylate polymer over 
approximately 7 days, directly into the CIED 
generator pocket. The sterile prosthesis is 
designed to hold a pacemaker or ICD generator, 
and while in the device pocket, will release 
minocycline and rifampin locally. 
In vivo studies using bacterial challenge 
by direct  device pocket inoculation 
show protection against the CoNS strain 
Staphylococcus epidermidis, S. aureus, Escherichia 
coli, Hemophiliussp., and Corynebacteriumsp.22 
Initial in vivo pre-clinical studies showing 
potential efficacy for the reduction of device 
pocket infection provided the basis for a recently 
published large cohort study.23
The Cooperative Multicenter study 
Monitoring a CIED Antimicrobial Device 
Figure 1. Rate of cardiovascular implantable electronic device (CIED)-related infection and incidence of comorbidities in 
patients with CIED infection.2  Adapted from Greenspon AJ, et al. 16-year trends in the infection burden for pacemakers and 
implantable cardioverter defibrillators in the United States 1993-2008. J Am Coll Cardiol. 2011;58:1001-1006. Copyright 
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(COMMAND) retrospective cohort study 
published by Bloom et al. in 2010 analyzed 
AIGISRx device implantation success, and 
resultant CIED infection rates, in 624 eligible 
patients over a study period from June 2008 to 
June 2009 with a mean follow-up of 1.9 months. 
Nearly half the patients had at least three pre-
defined risk factors for CIED infection. Infection 
was confirmed in three of the 624 patients 
(0.48%).11 All three infections occurred in 
patients undergoing a revision or generator 
replacement procedure, known to be associated 
with higher risk. There were no infections in the 
initial or fresh pacemaker, ICD, or CRT system 
implant cases. Device replacement or revision 
procedures have been previously shown to 
have higher rates of infection (OR 2.24-3.67).11
The relative avascularity of the remnant fibrous 
capsule may contribute to this risk by reducing 
delivery of systemic intravenous antibiotic 
prophylaxis to the device generator pocket. 
More than two-thirds (68%) of the procedures 
in the COMMAND study were for replacement 
or revision. In addition, several other known 
risk factors for CIED infection were common 
in the COMMAND study population, including 
congestive heart failure, greater than two leads 
in place (CRT systems or abandoned hardware), 
oral anticoagulant use, and renal insufficiency.11 
Limitations of the COMMAND study include 
its retrospective, nonrandomized nature, no 
direct control group set to compare infection 
rates internally (used prior published ICD 
registry data), and a short follow-up period. Two 
ongoing clinical prospective multicenter registry 
studies are currently enrolling patients; these are 
funded by TYRX, Inc., but are nonrandomized 
without a corresponding control group: (1) the 
AIGISRx Antibacterial Envelope and custom 
mesh for prevention of infection following 
cardiac rhythm management device replacement 
with an ICD (CITADEL), and (2) the AIGISRx 
Antibacterial Envelope and custom mesh for 
prevention of infection following cardiac rhythm 
management device replacement with a CRT 
device (CENTURION). To date, no randomized, 
controlled data are available with the use of this 
product to reduce CIED-related infection. 
AUTHORS EXPERIENCE AND 
PRELIMINARY DATA FROM 
VANDERBILT HEART AND 
VASCULAR INSTITUTE
Beginning in August 2009, the AIGISRx 
Antibacterial Envelope became available for use 
at Vanderbilt University Hospital, Nashville, TN, 
USA. In accordance with institutional policy on 
new product use, restrictions were placed on 
utilization, based on available clinical studies, 
and expert opinion. The use of the device has 
since been limited to patients with two or more 
of the following high-risk features for device-
related infection: diabetes (type I or II), renal 
insufficiency (creatinine ≥1.5 mg/dL), systemic 
anticoagulation, chronic daily steroid use, fever 
≥38°C or leukocytosis ≥11,000 WBC/µL within 
24 hours of the time of implantation, prior CIED 
infection, three or more leads (CRT systems or 
abandoned hardware), pacemaker dependence, 
or early pocket re-entry within 72 hours. 
Retrospective case-control data will be 
submitted from Vanderbilt Heart and Vascular 
Institute for publication, with matched 
internal controls derived from the Institute’s 
computerized patient record database. The time 
period for controls will be CIED infection rates 
in high-risk patients for the 2 year period prior 
to availability of the antibacterial envelope, 
compared to infection rates over the ensuing 
24 months (no added institutional changes 
occurred to operating room space, operating 
physicians, or operating room protocols during 
this time period). This will be the first study 
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with a corresponding internal control group to 
evaluate the effect of the AIGISRx Antibacterial 
Envelope on high-risk device infection rates at 
one institution, over a time period of 4 years. 
A cost-effectiveness calculation will be included 
with the submission. A randomized, prospective 
trial designed to assess the efficacy of the AIGISRx 
Antibacterial Envelope should be pursued. 
PRACTICAL ISSUES OF CONCERN 
INCLUDING IMPLANTATION 
TECHNIQUE 
A learning curve is apparent with the use of 
the AIGISRx Antibacterial Envelope. The device 
sleeve comes in two sizes, one for typical 
pacemaker generators, and a second intended for 
use with ICD systems. The device has a 3-4 mm 
seam along three of its four edges (rectangular 
shaped), which is the fusion of two flat sheets 
of polypropylene mesh. A pre-formed opening, 
which extends roughly 80% of the length of one 
of the shorter sides, is intended for insertion 
of the device generator. The mesh has a high 
coefficient of friction, and will require upsizing 
the subcutaneous device pocket 10%-15% by 
volume to allow ease of entry. During device 
implantation, the sleeve should house the CIED 
generator and pacemaker or ICD leads, which 
may need to be altered depending on the CIED 
manufacturer. Inverting the AIGISRx device to 
turn the seam to the inside of the device allows 
easier entry of the generator, and extending the 
preformed edge to open the remaining sealed 
portion may facilitate implantation. 
The device should not be left submerged in 
saline or antibacterial solution, as the minocycline-
rifampin granules may dissolve off the envelope 
and reduce efficacy (will see orange discoloration 
of fluid in which the device is left soaking). 
Gently moistening the sleeve immediately prior 
to insertion in the pocket with saline will facilitate 
entry; however, the more important consideration 
is making the pocket larger by more extensive 
dissection. Routine practice involves aggressive 
irrigation of the subcutaneous device pocket once 
all hardware is inserted (often with polymixin-
bacitracin solution). This should be avoided 
after the envelope is placed, as granules will 
also be irrigated or aspirated away in the flush. 
The practice of the present authors has been to 
insert the device leads fully in the pocket, then 
irrigate, wet, and invert the AIGISRx Antibacterial 
Envelope, place the generator in the envelope, 
connect leads to the device, and then place the 
generator and AIGISRx above the device leads in 
the subcutaneous pocket. With this technique, 
implantation will maximize the efficacy of 
the antibiotic granules and facilitate insertion
(Figure 2).
Figure 2. Implantable antibacterial envelope, AIGISRx, 
implantable cardioverter defibrillator (ICD) device 
(original photo taken by author).
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Extraction or removal of the AIGISRx upon 
device generator change, or revision after
2-3 months from initial implant, will require 
careful dissection. The recommendation from 
TYRX, Inc., is to dissect the envelope and device 
generator together as a unit, if necessary, as the 
device itself may be very difficult to see, as it 
is white and opaque, within a fibrotic capsule. 
Ideally to remove avascular tissue and the 
original sleeve, the entire system may need to 
be resected free. In underweight patients (body 
mass index <20) this may not be possible, and 
if there is adequate space a new AIGISRx may 
be implanted inside a prior device, though this 
may be challenging. Newer generation AIGISRx 
Antibacterial Envelopes with a thinner skeleton, 
or potentially bioabsorbable sleeves, which are 
currently under FDA review, may alleviate this 
concern. 
POTENTIAL COST-EFFECTIVENESS 
FOR THE AIGISRx ANTIBACTERIAL 
ENVELOPE
The rate of device-related infection is steadily 
rising, and given the large volume and cost of 
CIED-related infection hospitalizations, the 
estimated minimum cost burden to the US 
healthcare system exceeds $285 million. The 
estimated absolute risk reduction associated 
with the use of the AIGISRx device is 2.5%, 
and would generate a number needed to treat 
to prevent one infection of 40. At a unit price 
of $895 for an AIGISRx ICD envelope, a cost 
to hospitals for a single CIED-related infection 
of $35,800 for ICDs would be the break-even 
point. Data from Sohail et al. suggest that US 
hospitals could be expected to recoup $17,549 
dollars for each ICD-related infection that was 
prevented.4 This does not take into account 
the possibility that if applied appropriately, 
mortality from device-related infection could be 
reduced, though large, multicenter, randomized 
data would likely be needed to support this 
hypothesis.
CONCLUSIONS
CIED-related infections, typically resulting from 
Staphylococcus spp., are rising at a rate faster 
than the growth in new device implants. The 
rise correlates with increased numbers of CRT 
systems, laser lead extractions, and the growing 
prevalence of patients with diabetes or renal 
insufficiency undergoing procedures. The cost 
and morbidity of device-related infection is 
of great concern. Greater still is the mortality 
risk associated with a complicated hospital 
course for an infection related to a seemingly 
minor operation, such as a device generator 
change. Randomized data support the use of 
chlorhexidine surgical prep and preoperative 
antibiotic prophylaxis to reduce this risk. The 
AIGISRx Antibacterial Envelope offers a novel, 
cost-effective, locally delivered solution to 
further reduce this risk, particularly in the 
highest risk patient populations. Randomized 
trial data are required, and may be expected 
to demonstrate improved safety, cost, and 
potentially a reduction in mortality as it relates 
to a growing healthcare issue.
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